| BIOGEN INC. DL -,0005 | 264.050 / +0.23% |
| Date/Time | 12/12 / 17:01 |
| Chg. / Chg.(%) | 0.600 / +0.23% |
| Bid | 263.950 / 2000 |
| Ask | 264.300 / 2000 |
| Open | 260.500 |
| Previous Close | 263.450 |
| High | 265.100 |
| Low | 260.500 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 3 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Stuttgart |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 293.3250 |  |
775,999 |
| Cboe US | 293.71 | |
58,556 |
| IEX | 293.32 | |
47,713 |
| TradeGate | 264.950 | |
1,182 |
| London Inter.. | 293.47 | |
614 |
| Xetra | 264.10 | |
42 |
| Frankfurt | 264.7000 |  |
40 |
| Vienna Globa.. | 264.55 | |
0 |
| München | 261.25 | |
0 |
| Hamburg | 261.25 | |
0 |
| Düsseldorf | 264.00 | |
0 |
| Berlin | 263.70 | |
0 |
| Hannover | 261.25 | |
0 |
| Lang & Schwa.. | 263.750 | |
|
| gettex | 264.500 | |
|
| Stuttgart | 264.050 | |
|
| Mexico | 5,676.00 | |
5 |
| SIX Swiss Ex.. | 232.00 |
News
- Biogen stocks rise on new Alzheimer drug breakthrough
12/05/2019 / 19:26 - TeleTrader - Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
12/03/2019 / 13:30 - GlobeNewswire - Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
11/22/2019 / 13:30 - GlobeNewswire - Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
11/21/2019 / 13:30 - GlobeNewswire - AZTherapies Announces Appointment of Ernest D. Penachio as Vice President of Manufacturing Operations and CMC
11/06/2019 / 22:05 - GlobeNewswire
Real-time